Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

Risultato della ricerca: Contributo in rivistaArticolo in rivista

46 Citazioni (Scopus)

Abstract

Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event.
Lingua originaleEnglish
pagine (da-a)257-257-62.e3
RivistaJournal of the American Academy of Dermatology
Volume70
DOI
Stato di pubblicazionePubblicato - 2014

Keywords

  • 75% improvement in the Psoriasis Area Severity Index score
  • Adult
  • Analysis of Variance
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Cohort Studies
  • Confidence Intervals
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulin G
  • Italy
  • Male
  • Middle Aged
  • Multivariate Analysis
  • PASI
  • PASI 75
  • Predictive Value of Tests
  • Proportional Hazards Models
  • Psoriasis
  • Psoriasis Area Severity Index
  • Receptors, Tumor Necrosis Factor
  • Registries
  • Retrospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • TNF
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha
  • Young Adult
  • biologics
  • efficacy
  • primary inefficacy
  • psoriasis
  • secondary loss of efficacy
  • switching
  • tumor necrosis factor
  • tumor necrosis factor-alfa inhibitors

Fingerprint

Entra nei temi di ricerca di 'Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry'. Insieme formano una fingerprint unica.

Cita questo